Some aspects of application of the combination of formoterol and budesonide: what is changed?
https://doi.org/10.21518/2079-701X-2019-15-99-104
Abstract
The use of a combination of the inhaled glucocorticosteroid budesonide and beta2-selective long-acting adrenergic agonist formoterol is recommended for both bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD), however, indications for their use have changed significantly over the past 20 years. In BA, there was a transition from regular dosing to the tactics of a single drug – regularly and on demand, to the last recommendation – to apply as necessary at all stages of BA treatment. In COPD, this combination was a universal drug for the treatment of severe COPD with frequent exacerbations or in combination with BA, and now not only the severity and frequency of exacerbations, but also the level of blood eosinophilia is taken into account. The combination of budesonide / formoterol, which is important for practical health care, has become more accessible in recent years thanks to the advent of a domestic reconstituted drug with an original capsule powder inhaler. The drug went through comparative studies with the original drug both in clinical efficacy and in the properties of the delivered particles.
About the Authors
A. A. Vizel
Kazan State Medical University
Russian Federation
Russian Federation
Dr. of Sci. (Med.), Professor, Head of Chair for Phthisiopulmonology,
49 Butlerova Street, Kazan, 420012
I. Yu. Vizel
Kazan State Medical University;
Central Research Institute of Tuberculosis
Russian Federation
Russian Federation
Dr. of Sci. (Med.), Professor of RANH, Associate Professor of Chair for Phthisiopulmonology, 49 Butlerova Street, Kazan, 420012;
Researcher, 2 Yauzskaya Alley, Moscow, 107564
References
1. Tan K.S., Grove A., McLean A., Gnosspelius Y., Hall I.P., Lipworth B.J. Systemic corticosteriod rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. Am J Respir Crit Care Med. 1997;156(1):28-35. doi: 10.1164/ajrccm.156.1.9610113.
2. McGavin J.K., Goa K.L., Jarvis B. Inhaled budesonide/formoterol combination. Drugs. 2001;61(1):71-8; discussion 79-80. doi: 10.2165/00003495-200161010-00007.
3. Vizel A.A., Vizel I.Yu., Salakhova I.N., Vafina A.R. Adherence in bronchial asthma and chronic obstructive pulmonary disease: from a problem to a solution. Pharmateca = Farmateka. 2019;26(5):34-38. (In Russ.) doi: 10.18565/pharmateca.2019.5.122-126.
4. Partridge M.R., van der Molen T., Myrseth S.E., Busse W.W. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med. 2006;6:13. doi: 10.1186/1471-2466-6-13.
5. Vizel A.A., Vafina A.R., Vizel I.Yu., Salakhova I.N., Dyakova E.V., Kudryavtseva E.Z. Characteristics of patients with bronchial asthma have admitted to the stationares of the city of Kazan. Siberian Medical Review. 2017;(5):40-47. (In Russ.) doi: 10.20333/2500136-2017-5-40-47.
6. Sobieraj D.M., Weeda E.R., Nguyen E., Coleman C.I., White C.M., Lazarus S.C., Blake K.V., Lang J.E., Baker W.L. Association of inhaled corticosteroids and long-acting β-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis. JAMA. 2018;319(14):1485-1496. doi: 10.1001/jama.2018.2769.
7. Crisafulli E., Zanini A., Pisi G., Pignatti P. Poli G., Scuri M., Chetta A. Inhaled beclometasone dipropionate/formoterol fumarate extrafine fixed combination for the treatment of asthma. Expert Rev Respir Med. 2016;10(5):481-90. doi: 10.1586/17476348.2016.1161508.
8. Ignatova G.L., Belevskiy A.S. Modern techniques for inhalation drug delivery in the treatment of bronchial obstructive diseases. Astma i allergiya = Asthma and Allergy. 2018;(2):21-28. (In Russ.) Available at: http:// www.atmosphere-ph.ru/modules/Magazines/articles/astma/Asthma_2_2018_21.pdf.
9. Zyryanov S.K., Galeeva Zh.A., Belousov Yu.B. High-quality generics for treatment of broncho-obstructive diseases: There is a light at the end of the tunnel! Lechashchiy vrach = Attending Physician. 2014;(11):72-75. (In Russ.) Available at: https://www.lvrach.ru/2014/11/15436100/
10. Eliseeva E.V., Nevzorova V.A. Maneeva, E.S., Goncharova R.K. Medicine provision in case of diseases of the respiratory system: opportunities and solutions. RMZH = RMJ. 2018;10(I):28–35. (In Russ.) Available at: https://www.rmj.ru/articles/bolezni_dykhatelnykh_putey/Lekarstvennoe_obespechenie_pri_zabolevaniyah_organov_dyhaniya_vozmoghnosti_iresheniya/#ixzz62Jx0KVTx.
11. Belevsky A.S., Zaitsev A.A. Pharmacoeconomic aspects of bronchial asthma therapy: real clinical practice. Meditsinskiy sovet = Medical Council. 2018;(15):60-68. (In Russ.) doi: 10.21518/2079-701X-2018-15-60-68.
Review
For citations:
Vizel AA, Vizel IY. Some aspects of application of the combination of formoterol and budesonide: what is changed? Meditsinskiy sovet = Medical Council. 2019;(15):99-104. (In Russ.) https://doi.org/10.21518/2079-701X-2019-15-99-104
Views:
594
Email this article 